To evaluate the universal applicability of combining LIMK1 and CDK5 kinase inhibitors in tumor therapy, the Boyden chamber assay was performed in EAC, gastric cancer, and lung cancer cells. This evidence concerns the gene LIMK1 and neoplasm.